RBF Capital’s Dianthus Therapeutics DNTH Stock Holding History

RBF Capital’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$292K	Hold	3,000	–	–	0.01%	448
2026 Q1	$252K	Sell	3,000 -2,000	-40%	-$116K	0.01%	439
2025 Q4	$206K	Sell	5,000 -2,000	-29%	-$77.5K	0.01%	515
2025 Q3	$275K	Buy	+7,000	New	+$179K	0.01%	485
2024 Q4	–	Sell	-10,784	Closed	-$295K	–	563
2024 Q3	$295K	Hold	10,784	–	–	0.01%	506
2024 Q2	$279K	Hold	10,784	–	–	0.02%	488
2024 Q1	$324K	Hold	10,784	–	–	0.02%	458
2023 Q4	$112K	Sell	10,784 -4,892	-31%	-$54K	0.01%	522
2023 Q3	$214K	Hold	15,676	–	–	0.01%	461
2023 Q2	$190K	Hold	15,676	–	–	0.01%	468
2023 Q1	$199K	Sell	15,676 -5,663	-27%	-$62.7K	0.01%	452
2022 Q4	$135K	Sell	21,339 -1,875	-8%	-$33.2K	0.01%	489
2022 Q3	$524K	Hold	23,214	–	–	0.04%	327
2022 Q2	$446K	Buy	+23,214	New	+$574K	0.03%	359

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

RBF Capital's DNTH Position: Q2 2026 in Review

RBF Capital held its Dianthus Therapeutics (DNTH) position steady in Q2 2026 at 3,000 shares worth $292K. The position accounts for 0.01% of the portfolio, ranked #448.

RBF Capital first reported a position in DNTH in Q2 2022 and has held it in 14 quarters since. The position peaked at $524K in Q3 2022. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

RBF Capital held 3,000 shares of Dianthus Therapeutics worth $292K as of Q2 2026.
RBF Capital left its Dianthus Therapeutics share count unchanged in Q2 2026.
Dianthus Therapeutics made up 0.01% of RBF Capital's portfolio in Q2 2026, its #448 holding.
RBF Capital first reported a position in Dianthus Therapeutics in Q2 2022 and has held it in 14 quarters since.
RBF Capital's Dianthus Therapeutics position peaked at $524K in Q3 2022.
270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on RBF Capital's 13F filing for Q2 2026, filed 14 Aug 2026.